2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There have been some big moves in the healthcare sector on Thursday.

For example, the two ASX healthcare shares listed below are up at least 16% in morning trade thanks to big news in the United States.

Here's what you need to know about them:

Cyclopharm Ltd (ASX: CYC)

The Cyclopharm share price is up 18% to $1.80. Investors have been buying the ASX healthcare share this morning after it announced an interim agreement to supply the Veterans Health Administration (VA) with the pharmaceutical and consumable components of Technegas.

Technegas is the company's core radiopharmaceutical product, used in functional lung ventilation imaging.

This could be a very big deal for Cyclopharm given that the VA is the largest integrated US Government health care system in the United States.

According to the release, the interim agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for these products.

Cyclopharm's CEO, James McBrayer, commented:

Securing this Interim Agreement is critical for streamlining the United States Federal Government procurement process. This agreement bypasses the need for Cyclopharm to negotiate separate contracts with each of the 20 Regional Procurement Offices within the VA or potentially follow a reseller pathway that would delay the deployment of Technegas, distance us from our customers and impact margins beyond the legislated discounts required for federal contracts.

Lumos Diagnostics Holdings Ltd (ASX: LDX)

The Lumos Diagnostics share price is up 16% to 4.3 cents.

This has been driven by news that the point-of-care diagnostic technology provider has been awarded ~US$3 million from the Biomedical Advanced Research and Development Authority (BARDA). It is part of the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response.

These funds are to support the planned Clinical Laboratory Improvement Amendments (CLIA)-waiver clinical study and regulatory submission for Lumos' FebriDx bacterial/non-bacterial test.

FebriDx can aid clinicians with appropriate antibiotic use decisions and will hopefully improve antibiotic stewardship.

The ASX healthcare share's CEO and managing director, Doug Ward, commented,

Since early clinical practice, doctors have relied primarily on clinical observation to determine whether patients require antibiotics for acute respiratory conditions. FebriDx is a powerful diagnostic which can provide a quick and clear clinical evaluation, and in doing so, can reduce over-prescription of antibiotics.

Special mention goes to fellow ASX healthcare share Mesoblast Ltd (ASX: MSB), which is rising over 9% today. However, with no news out of the company, it remains unclear why investors are scrambling to buy its shares today.

Should you invest $1,000 in Cyclopharm Limited right now?

Before you buy Cyclopharm Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Cyclopharm Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »